Jeremy N. Rich, MD (Damon Runyon-Lilly Clinical Investigator '04-'09) and colleagues describe exciting results of a clinical trial for advanced gliomas, brain cancers with notoriously poor prognoses. Dr. Rich and collaborators show that 63% of patients in the trial had a radiographic response after treatment with the combination of bevacizumab and irinotecan and the 6-month survival probability was 72%. This represents a significant improvement for patients with advanced gliomas.

Click here for more.